The Impact of Chemotherapy-Induced Myelosuppression

home / insights / the-impact-of-chemotherapy-induced-myelosuppression

Chemotherapy Use & Chemotherapy-Induced Myelosuppression

EP. 1: Chemotherapy Use & Chemotherapy-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
Management of Chemo-Induced Myelosuppression

EP. 2: Management of Chemo-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
Chemotherapy-Induced Myelosuppression & COVID-19

EP. 3: Chemotherapy-Induced Myelosuppression & COVID-19

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
CDK4/6 Inhibitors and Myelopreservation

EP. 4: CDK4/6 Inhibitors and Myelopreservation

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
Analyses of CDK4/6 Inhibitors for Myelopreservation

EP. 5: Analyses of CDK4/6 Inhibitors for Myelopreservation

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

EP. 6: Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
CDK4/6 Inhibitors for SCLC: Trials of Interest

EP. 7: CDK4/6 Inhibitors for SCLC: Trials of Interest

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
CDK4/6 Inhibitors & Myelopreservation in Other Cancers

EP. 8: CDK4/6 Inhibitors & Myelopreservation in Other Cancers

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020
Reducing the Impact of Chemotherapy-Induced Myelosuppression

EP. 9: Reducing the Impact of Chemotherapy-Induced Myelosuppression

Paul Bunn, MD, University of Colorado Cancer Center;Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine
September 16th 2020